GSI 705 (Truvada 167 mg / 250 mg)
Generic Name: emtricitabine/tenofovir
Pill imprint GSI 705 has been identified as Truvada 167 mg / 250 mg.
Truvada is used in the treatment of pre-exposure prophylaxis; hiv infection; occupational exposure; nonoccupational exposure and belongs to the drug class antiviral combinations. There is no proven risk in humans during pregnancy. Truvada 167 mg / 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- emtricitabine/tenofovir
- Imprint:
- GSI 705
- Strength:
- 167 mg / 250 mg
- Color:
- Blue
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Antiviral combinations
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Gilead Sciences, Inc.
More about Truvada (emtricitabine / tenofovir)
Consumer resources
- Other brands: AccessPak for HIV PEP Basic
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
